WO2009030884A3 - Mannosylated butyrophilin tumour markers - Google Patents

Mannosylated butyrophilin tumour markers Download PDF

Info

Publication number
WO2009030884A3
WO2009030884A3 PCT/GB2008/002954 GB2008002954W WO2009030884A3 WO 2009030884 A3 WO2009030884 A3 WO 2009030884A3 GB 2008002954 W GB2008002954 W GB 2008002954W WO 2009030884 A3 WO2009030884 A3 WO 2009030884A3
Authority
WO
WIPO (PCT)
Prior art keywords
mannosylated
butyrophilin
tumour markers
btns
butyrophilins
Prior art date
Application number
PCT/GB2008/002954
Other languages
French (fr)
Other versions
WO2009030884A2 (en
Inventor
John Trowsdale
Georg Malcherek
Original Assignee
Cambridge Entpr Ltd
John Trowsdale
Georg Malcherek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd, John Trowsdale, Georg Malcherek filed Critical Cambridge Entpr Ltd
Publication of WO2009030884A2 publication Critical patent/WO2009030884A2/en
Publication of WO2009030884A3 publication Critical patent/WO2009030884A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention relates to the finding that butyrophilins (BTNs) are mannosylated when expressed by cancer cells. Methods and compositions relating to the detection and treatment of cancer cells expressing mannosylated butyrophilins (BTNs) are provided.
PCT/GB2008/002954 2007-09-03 2008-09-01 Mannosylated butyrophilin tumour markers WO2009030884A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0717101.0A GB0717101D0 (en) 2007-09-03 2007-09-03 Tumour marker
GB0717101.0 2007-09-03

Publications (2)

Publication Number Publication Date
WO2009030884A2 WO2009030884A2 (en) 2009-03-12
WO2009030884A3 true WO2009030884A3 (en) 2009-06-04

Family

ID=38617179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002954 WO2009030884A2 (en) 2007-09-03 2008-09-01 Mannosylated butyrophilin tumour markers

Country Status (2)

Country Link
GB (1) GB0717101D0 (en)
WO (1) WO2009030884A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031736A2 (en) * 2009-09-14 2011-03-17 The Rockefeller University Methods of identifying anti-inflammatory compounds
US20160376364A1 (en) * 2013-11-29 2016-12-29 Csl Limited Method of treating cancer
CN105457024B (en) * 2014-10-13 2021-03-16 李小彦 Anti-butyrophilin-3 humanized antibody and use thereof
WO2016191305A1 (en) * 2015-05-22 2016-12-01 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
KR20180100122A (en) 2015-12-02 2018-09-07 주식회사 에스티사이언스 Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor)
WO2017096051A1 (en) * 2015-12-02 2017-06-08 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
AU2018277838A1 (en) * 2017-05-31 2019-12-19 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
AU2018277545A1 (en) * 2017-05-31 2019-12-19 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
JP2020522562A (en) 2017-06-06 2020-07-30 ストキューブ アンド シーオー．， インコーポレイテッド Methods of treating cancer with antibodies and molecules that bind to BTN1A1 or BTN1A1 ligand
MX2020003219A (en) * 2017-09-21 2020-07-20 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof.
EP3902557A4 (en) 2019-01-07 2023-06-07 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
EP3696191A1 (en) * 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer
AU2020243076A1 (en) * 2019-03-20 2021-10-14 Centre National De La Recherche Scientifique - Cnrs - Antibodies having specificity for BTN2 and uses thereof
KR20220100567A (en) * 2019-06-28 2022-07-15 더 유니버시티 오브 멜버른 Methods of Inhibiting or Activating Gamma Delta T Cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134671A1 (en) * 2004-11-22 2006-06-22 Wyeth Methods and systems for prognosis and treatment of solid tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134671A1 (en) * 2004-11-22 2006-06-22 Wyeth Methods and systems for prognosis and treatment of solid tumors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DILLEY WILLIAM G ET AL: "Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, vol. 4, no. 1, 3 February 2005 (2005-02-03), pages 9, XP021008272, ISSN: 1476-4598 *
GUGGENMOS JOHANNES ET AL: "Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JAN 2004, vol. 172, no. 1, 1 January 2004 (2004-01-01), pages 661 - 668, XP002509855, ISSN: 0022-1767 *
JOHNSON V G ET AL: "Monoclonal antibodies prepared against PAS-I butyrophilin and GP-55 from guinea-pig milk-fat-globule membrane bind specifically to the apical pole of secretory-epithelial cells in lactating mammary tissue", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 158, no. 1, 1 May 1985 (1985-05-01), pages 144 - 158, XP024852400, ISSN: 0014-4827, [retrieved on 19850501] *
MALCHEREK GEORG ET AL: "The B7 homolog butyrophilin BTN2A1 is a novel ligand for DC-SIGN.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 SEP 2007, vol. 179, no. 6, 15 September 2007 (2007-09-15), pages 3804 - 3811, XP002509857, ISSN: 0022-1767 *
OLIVE D: "B7/butyrophilin family members are leading the race for immune intervention", EXPERT OPINION ON THERAPEUTIC PATENTS 200703 GB, vol. 17, no. 3, March 2007 (2007-03-01), pages 357 - 359, XP002509856, ISSN: 1354-3776 *
STEFFERL A ET AL: "Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 165, no. 5, 1 September 2000 (2000-09-01), pages 2859 - 2865, XP002206101, ISSN: 0022-1767 *
SUN-LONG CHENG ET AL: "Toxicogenomics of A375 human malignant melanoma cells treated with arbutin", JOURNAL OF BIOMEDICAL SCIENCE, KLUWER ACADEMIC PUBLISHERS, DO, vol. 14, no. 1, 11 November 2006 (2006-11-11), pages 87 - 105, XP019485506, ISSN: 1423-0127 *

Also Published As

Publication number Publication date
WO2009030884A2 (en) 2009-03-12
GB0717101D0 (en) 2007-10-10

Similar Documents

Publication Publication Date Title
WO2009030884A3 (en) Mannosylated butyrophilin tumour markers
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2010077740A3 (en) Novel antiviral compounds, compositions, and methods of use
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2009111643A3 (en) Microrna markers for recurrence of colorectal cancer
WO2008089397A3 (en) Adrb2 cancer markers
WO2010062396A3 (en) Virus like particle compositions and methods of use
WO2012048099A3 (en) Nanoparticle-loaded cells
WO2012061290A3 (en) Pesticidal compositions and processes related thereto
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2008134761A3 (en) Modification of biological targeting groups for the treatment of cancer
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
WO2011133722A3 (en) Anti-viral compounds
WO2008115262A3 (en) Hsp90 inhibitors containing a zinc binding moiety
WO2010011407A3 (en) Methods of generating patterned soft substrates and uses thereof
WO2012042386A3 (en) Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
WO2011090949A3 (en) Methods and compositions for processing chemical reactions
WO2009077471A3 (en) Azolylmethyloxiranes, use thereof and agents containing the same
WO2010012751A3 (en) Reduced sesame seed derived pigments
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
AU2007249926A8 (en) Monocyclic heteroaryl compounds
WO2011005594A3 (en) Antimicrobial compositions and methods of making and using the same
WO2009002440A3 (en) Compositions comprising human egfr-sirna and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08788497

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08788497

Country of ref document: EP

Kind code of ref document: A2